Shortening duration of ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections: A retrospective study.

ABSTRACT:

Background

The incidence of multi-drug resistant ESBL-associated urinary tract infections (UTIs) is increasing globally. Patients with abnormal renal tract anatomy and other co-morbidities are at increased risk of complicated UTI and ESBL-associated infections. The duration and safety of OPAT for this cohort of patients is unknown.

Objectives

This study aims to provide an evidence base to support decision-making regarding duration of antibiotic treatment for complicated UTIs.

Methods

We retrospectively reviewed all patients receiving ertapenem with or without adjunctive fosfomycin for complicated UTIs in the OPAT service of our tertiary infectious diseases hospital. All data had been collected prospectively as part of routine clinical care. Our primary outcomes were m

SUBMITTER: Fink DL 

PROVIDER: S-EPMC6762133 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature